Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25105378 | 1.00 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL25104882 | 1.00 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL25104905 | 0.97 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL2707862 | 0.95 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1863662 | 0.95 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1863664 | 0.95 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL25249532 | 0.92 | SLC6A2 (0.39) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL29138125 | 0.92 | SLC6A2 (0.39) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL13144562 | 0.92 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL27740053 | 0.90 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400584-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023034836-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2011121309-A1 | PHENYL SULFONYL DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400584-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SLC6A4 3351/4885SLC6A2 4098/4885SLC6A3 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.